Wycena firm — Clinic Rollup / DSO
Dla kogo jest ta wycena
PE-backed DSO and clinic rollup operators evaluating platform value and add-on targets, and independent practice owners considering joining a DSO platform or selling to a strategic acquirer.
Co napędza wartość w branży Clinic Rollup / DSO
- Number of sites and same-store EBITDA growth across locations
- De novo opening track record and pipeline of signed LOIs
- Associate provider density and non-compete provisions
- Specialty mix: general practice versus higher-margin specialties (ortho, endo, perio)
- Insurance credentialing breadth and commercial payer contract terms
- Central services infrastructure reducing per-site overhead
Metody wycen, które stosujemy
DSOs and clinic platforms are valued at 8–16× EBITDA, with larger platforms commanding the high end due to central services leverage and de novo optionality. Individual practices acquired by DSOs typically trade at 4–7× EBITDA. This tool is informational only. Output is driven by your inputs and does not constitute a formal appraisal or certified valuation.
Typowe metryki i dane wejściowe
Site-level EBITDA margin
Four-wall EBITDA per location; the primary measure of individual practice health.
De novo success rate
Percentage of new clinics reaching target EBITDA within 24 months; key platform scalability signal.
Collections per provider day
Daily production collections per active provider; benchmarked to specialty norms.
Same-store EBITDA growth
Year-over-year EBITDA growth at locations open 18+ months.
Associate-to-owner ratio
Number of associate providers per partner; higher ratio increases platform scalability.
Przykładowe scenariusze
20-location dental DSO
A DSO with 20 locations, $8 M platform EBITDA, and a proven de novo playbook might be valued at 12–15× EBITDA in a PE secondary.
Single-specialty optometry rollup
A 10-location optometry platform with $3 M EBITDA and strong commercial payer mix might trade at 9–11× EBITDA.
Często zadawane pytania
What multiple does a DSO sell for?
Platform DSOs with 10+ sites: 10–16× EBITDA. Individual dental practices selling into a DSO: 4–7× EBITDA.
Why do DSO platforms get higher multiples than individual practices?
Central services reduce per-site costs, de novo pipelines create growth optionality, and platform infrastructure reduces key-person risk - all commanding premium multiples.
How are de novo openings valued?
A proven de novo playbook adds significant option value. Buyers model the NPV of future site openings based on historical ramp-to-profitability timelines.
What specialties command the highest multiples in dental?
Orthodontics and oral surgery typically earn higher multiples than general dentistry due to higher margins and more predictable case mix.
Is this a certified appraisal?
No. This tool provides informational estimates. For DSO M&A, engage a healthcare-focused M&A advisor.
Uruchom swoją wycenę — Clinic Rollup / DSO
Otrzymaj profesjonalny raport wyceny oparty na DCF, spółkach porównywalnych, transakcjach precedensowych i analizie scenariuszy — za jedyne 199 USD.
Powiązane branże
Healthcare Services
Value a healthcare services company using EBITDA multiples, revenue per provider, and payer mix analysis. AI-powered reports for $199.
Medical Labs
Value a clinical laboratory, pathology lab, or diagnostic testing company using EBITDA multiples and revenue per accession analysis. Reports for $199.
Healthcare Devices
Value a medical device company using revenue multiples, regulatory clearance premium, and pipeline analysis. Reports for $199.